Our clinical programs focus on hematologic malignancies, non-oncology rare disease, and solid tumors.

Our most advanced TCR T-cell therapy programs, TCX-101 and TCX-102, are a best-in-class portfolio for high-risk leukemia patients designed to address multiple critical points in AML disease progression to have a high impact on survival.

TCX-101

  • TCR T-cell therapy given in conjunction with standard of care stem cell transplant (alloSCT).
  • Designed to expand the patient population eligible for alloSCT.

TCX-102

  • TCR T-cell therapy for patients with NPM1 mutated AML.
  • Reaches patients ineligible for alloSCT with limited therapeutic options.

Discovery

IND-ENABLING

PHASE 1

HEMATOLOGIC

Discovery

IND-Enabling

PHASE 1

BSB-1001: Blood Restricted #1 – HA-1
BSB-1001: Blood Restricted #1 – HA-1

IND Accepted

Discovery

IND-Enabling

PHASE 1

Blood Restricted #2
Blood Restricted #2

Discovery

IND-Enabling

PHASE 1

Blood Restricted #3
Blood Restricted #3

Discovery

IND-Enabling

PHASE 1

Blood Restricted #4
Blood Restricted #4

Discovery

IND-Enabling

PHASE 1

TCX-102: AML mutNPM1
TCX-102: AML mutNPM1

SOLID TUMOR

Discovery

IND-Enabling

PHASE 1

TCX-301
TCX-301
RARE DISEASE

Discovery

IND-Enabling

PHASE 1

Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis (RRP)

IND Submitted

Contact us to hear more about our clinical programs and technology.